India · COPD Exacerbation · Acute Severe Asthma · Bronchospasm · Nebuliser · MDI · Ipravent · Duolin · Combivent · Ipradulin
⚠️ Avoid nebuliser mist near eyes — may worsen narrow-angle glaucoma. Use mouthpiece, not face mask, where possible.
⚠️ Prostatic hyperplasia — may cause urinary retention at high doses
⚠️ Not for acute bronchospasm as monotherapy — salbutamol first
✅ Safe in pregnancy and breastfeeding
✅ Safe in cardiovascular disease (preferred over high-dose salbutamol in IHD)
| Patient / Route | Dose | Frequency | Indication |
|---|---|---|---|
| Adult nebuliser | 500 mcg (2ml unit dose) | Every 6–8h maintenance; every 4–6h acute exac | COPD maintenance / exacerbation |
| Adult MDI | 2 puffs (40 mcg) | 3–4 times daily (TDS–QDS) | COPD maintenance |
| Child 5–12yr nebuliser | 250 mcg (1ml unit dose) | Every 6–8h; every 20 min × 3 acute | Acute severe asthma |
| Child <5yr nebuliser | 125–250 mcg | Every 6–8h | Acute wheeze |
| Child MDI + spacer | 2 puffs (40 mcg) | 3 times daily | Add-on to salbutamol |
| Acute severe asthma (adult) | 500 mcg nebulised | Every 20 min × 3 doses then reassess | Combined with salbutamol 5mg neb |
| Duolin (combined) | 1 unit dose (ipra 500 + salb 2.5mg) | TDS–QDS or PRN acute | COPD / acute bronchospasm |
Ipratropium bromide is a short-acting muscarinic antagonist (SAMA) bronchodilator that blocks cholinergic-mediated bronchoconstriction. It is the anticholinergic counterpart to salbutamol (SABA) and provides complementary — and synergistic — bronchodilation via a different mechanism. In India, ipratropium is extensively used in COPD management, both alone (nebuliser or MDI) and in fixed combinations with salbutamol (Duolin, Combivent). Its particular importance in Indian clinical practice relates to the very high prevalence of COPD caused by biomass fuel combustion, occupational dust exposure, and tobacco use.
In acute severe or life-threatening asthma, the combination of nebulised ipratropium 500 mcg with salbutamol 5 mg produces significantly greater bronchodilation than either drug alone — GINA and BTS guidelines recommend this combination as standard treatment. The ipratropium should be given every 20 minutes for the first 3 doses alongside back-to-back salbutamol, then reassessed. In children with acute severe asthma, ipratropium 250 mcg every 20 minutes × 3 is similarly recommended. Duolin (ipratropium 500 mcg + salbutamol 2.5 mg in one 2.5 ml unit dose) is the most practical combined formulation widely available in India, though the doses of each component may need adjustment for optimal therapy.
For mild COPD in India, ipratropium MDI 2 puffs (40 mcg) three to four times daily remains a commonly used, affordable maintenance bronchodilator. Long-acting alternatives (tiotropium, glycopyrronium, umeclidinium) are preferred in guidelines for sustained COPD management but their cost is prohibitive for many patients in India — ipratropium serves as an accessible alternative. For moderate-severe COPD exacerbations admitted to hospital, nebulised ipratropium 500 mcg every 6 hours (combined with salbutamol) is standard inpatient practice across most Indian hospitals.